Physician profile
Christopher P Long
NPI 1023634516
$6,063.85
in general payments reported to CMS, 2019-2025
15 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.64 · 2022: $398 · 2023: $2,928 · 2024: $1,286 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,001 · Travel and Lodging: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,000.60 |
| Travel and Lodging | $1,641.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,298.44 | 2023-2025 | Envista Mx60 Iol, Stellaris Elite, Trulign Iol |
| Alcon Vision LLC | $2,296.30 | 2021-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Abbvie INC. | $399.97 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $347.86 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $188.84 | 2024-2025 | Iolmaster 700, Quatera 700, Lumera 700 |
| Johnson & Johnson Surgical Vision, INC. | $131.99 | 2024-2025 | Catalys System, Tecnis Iol, Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $96.45 | 2024-2025 | |
| Thea Pharma INC. | $67.93 | 2025 | Iyuzeh |
| Harrow Eye, LLC | $50.28 | 2025 | Vevye |
| Amgen INC. | $46.02 | 2025 | Tepezza |
| Sight Sciences, INC. | $39.70 | 2025 | Omni Surgical System |
| Oyster Point Pharma, INC. | $30.65 | 2024 | Tyrvaya |
| Ani Pharmaceuticals, INC. | $26.14 | 2025 | Purified Cortrophin Gel |
| Dompe US, INC. | $25.19 | 2025 | Oxervate |
| Rxsight INC | $18.09 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.